476 related articles for article (PubMed ID: 27668357)
1. Efficacy and Safety of Rituximab Therapy in Neuromyelitis Optica Spectrum Disorders: A Systematic Review and Meta-analysis.
Damato V; Evoli A; Iorio R
JAMA Neurol; 2016 Nov; 73(11):1342-1348. PubMed ID: 27668357
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of rituximab in the treatment of neuromyelitis optica spectrum disorders: An update systematic review and meta -analysis.
Wang Y; Chang H; Zhang X; Yin L
Mult Scler Relat Disord; 2021 May; 50():102843. PubMed ID: 33609924
[TBL] [Abstract][Full Text] [Related]
3. Long-term tolerability, safety and efficacy of rituximab in neuromyelitis optica spectrum disorder: a prospective study.
Shaygannejad V; Fayyazi E; Badihian S; Mirmosayyeb O; Manouchehri N; Ashtari F; Asgari N
J Neurol; 2019 Mar; 266(3):642-650. PubMed ID: 30635724
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of rituximab in myelin oligodendrocyte glycoprotein antibody-associated disorders compared with neuromyelitis optica spectrum disorder: a systematic review and meta-analysis.
Spagni G; Sun B; Monte G; Sechi E; Iorio R; Evoli A; Damato V
J Neurol Neurosurg Psychiatry; 2023 Jan; 94(1):62-69. PubMed ID: 36283808
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial.
Tahara M; Oeda T; Okada K; Kiriyama T; Ochi K; Maruyama H; Fukaura H; Nomura K; Shimizu Y; Mori M; Nakashima I; Misu T; Umemura A; Yamamoto K; Sawada H
Lancet Neurol; 2020 Apr; 19(4):298-306. PubMed ID: 32199095
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of rituximab in neuromyelitis optica: a meta-analysis.
Gao F; Chai B; Gu C; Wu R; Dong T; Yao Y; Zhang Y
BMC Neurol; 2019 Mar; 19(1):36. PubMed ID: 30841862
[TBL] [Abstract][Full Text] [Related]
7. A long-term follow-up of rituximab treatment in 20 Chinese patients with neuromyelitis optica spectrum disorders.
Lu Q; Luo J; Hao H; Liu R; Jin H; Jin Y; Gao F
Mult Scler Relat Disord; 2020 May; 40():101933. PubMed ID: 31955136
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of effect of empirical attack-preventive immunotherapies in neuromyelitis optica spectrum disorders: An update systematic review and meta -analysis.
Ma J; Yu H; Wang H; Zhang X; Feng K
J Neuroimmunol; 2022 Feb; 363():577790. PubMed ID: 34959021
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Monoclonal Antibody Therapy in Neuromyelitis Optica Spectrum Disorders: Evidence from Randomized Controlled Trials.
Xue T; Yang Y; Lu Q; Gao B; Chen Z; Wang Z
Mult Scler Relat Disord; 2020 Aug; 43():102166. PubMed ID: 32442886
[TBL] [Abstract][Full Text] [Related]
10. A meta-analysis on efficacy and safety of rituximab for neuromyelitis optica spectrum disorders.
Dong GY; Meng YH; Xiao XJ
Medicine (Baltimore); 2022 Sep; 101(36):e30347. PubMed ID: 36086713
[TBL] [Abstract][Full Text] [Related]
11. Treatment Outcomes With Rituximab in 100 Patients With Neuromyelitis Optica: Influence of FCGR3A Polymorphisms on the Therapeutic Response to Rituximab.
Kim SH; Jeong IH; Hyun JW; Joung A; Jo HJ; Hwang SH; Yun S; Joo J; Kim HJ
JAMA Neurol; 2015 Sep; 72(9):989-95. PubMed ID: 26167726
[TBL] [Abstract][Full Text] [Related]
12. Impact of Rituximab on relapse rate and disability in an Ecuadorian cohort of patients with neuromyelitis optica spectrum disorders.
Correa-Díaz EP; Torres-Herrán GE; Miño Zambrano JE; Paredes-Gonzalez V; Caiza-Zambrano FJ
Mult Scler Relat Disord; 2021 Feb; 48():102683. PubMed ID: 33338945
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of treatments in Neuromyelitis optica to modify the course of disease in adult patients. Systematic review of literature.
Velasco M; Zarco LA; Agudelo-Arrieta M; Torres-Camacho I; Garcia-Cifuentes E; Muñoz O
Mult Scler Relat Disord; 2021 May; 50():102869. PubMed ID: 33711580
[TBL] [Abstract][Full Text] [Related]
14. Rituximab abrogates aquaporin-4-specific germinal center activity in patients with neuromyelitis optica spectrum disorders.
Damato V; Theorell J; Al-Diwani A; Kienzler AK; Makuch M; Sun B; Handel A; Akdeniz D; Berretta A; Ramanathan S; Fower A; Whittam D; Gibbons E; McGlashan N; Green E; Huda S; Woodhall M; Palace J; Sheerin F; Waters P; Leite MI; Jacob A; Irani SR
Proc Natl Acad Sci U S A; 2022 Jun; 119(24):e2121804119. PubMed ID: 35666871
[TBL] [Abstract][Full Text] [Related]
15. Anti-Rituximab antibody in patients with NMOSDs treated with low dose Rituximab.
Li T; Zhang LJ; Zhang QX; Yang CS; Zhang C; Li YJ; Shi FD; Yang L
J Neuroimmunol; 2018 Mar; 316():107-111. PubMed ID: 29310942
[TBL] [Abstract][Full Text] [Related]
16. Rituximab as first-line therapy in neuromyelitis optica: efficiency and tolerability.
Zéphir H; Bernard-Valnet R; Lebrun C; Outteryck O; Audoin B; Bourre B; Pittion S; Wiertlewski S; Ouallet JC; Neau JP; Ciron J; Clavelou P; Marignier R; Brassat D
J Neurol; 2015 Oct; 262(10):2329-35. PubMed ID: 26194198
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and tolerability of azathioprine for neuromyelitis optica spectrum disorder: A systematic review and meta-analysis.
Espiritu AI; Pasco PMD
Mult Scler Relat Disord; 2019 Aug; 33():22-32. PubMed ID: 31136907
[TBL] [Abstract][Full Text] [Related]
18. Clinical and therapeutic predictors of disease outcomes in AQP4-IgG+ neuromyelitis optica spectrum disorder.
Kunchok A; Malpas C; Nytrova P; Havrdova EK; Alroughani R; Terzi M; Yamout B; Hor JY; Karabudak R; Boz C; Ozakbas S; Olascoaga J; Simo M; Granella F; Patti F; McCombe P; Csepany T; Singhal B; Bergamaschi R; Fragoso Y; Al-Harbi T; Turkoglu R; Lechner-Scott J; Laureys G; Oreja-Guevara C; Pucci E; Sola P; Ferraro D; Altintas A; Soysal A; Vucic S; Grand'Maison F; Izquierdo G; Eichau S; Lugaresi A; Onofrj M; Trojano M; Marriott M; Butzkueven H; Kister I; Kalincik T
Mult Scler Relat Disord; 2020 Feb; 38():101868. PubMed ID: 31877445
[TBL] [Abstract][Full Text] [Related]
19. Disease course, progression and activity of neuromyelitis optica (NMOSD) in patients who were treated with Rituximab, 6 and 12 months after receiving the first dose of drug, in Isfahan city.
Ashtari F; Mehdipour R; Shaygannejad V; Mansourian M
Mult Scler Relat Disord; 2019 Sep; 34():77-82. PubMed ID: 31233958
[TBL] [Abstract][Full Text] [Related]
20. Different doses of Rituximab for the therapy of Neuromyelitis optica spectrum disorder: A systematic review and meta-analysis.
Wei K; Nie Q; Zhu Y; Lu H; Xue Q; Chen G
Mult Scler Relat Disord; 2022 Dec; 68():104127. PubMed ID: 36044828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
